Earnings Feed
Start Free
MoonLake Immunotherapeutics·4

Jun 22, 4:50 PM ET

BIOTECHNOLOGY VALUE FUND L P 4

Research Summary

AI-generated summary

Updated

MoonLake (MLTX) 10% Owner BVF Partners Receives 22,195-Share Option Award

What Happened
BVF Partners L.P., part of a Section 13(d) group that owns >10% of MoonLake Immunotherapeutics (MLTX), was granted a derivative award on June 17, 2026: an option/award representing the right to acquire 22,195 Class A ordinary shares of the company. The reported exercise/acquisition price is $0.00, so no cash was paid at grant and no immediate sale/purchase of common shares occurred.

Key Details

  • Transaction date: June 17, 2026; Form 4 filed June 22, 2026 (filed 5 calendar / 3 business days after the transaction — late filing).
  • Transaction type/code: A (Grant / award or other acquisition); derivative instrument representing 22,195 shares.
  • Price/strike: $0.00 per share (as reported). Reported total immediate cash value: $0.
  • Vesting/conditions: Footnote F5 states the option vests in full upon the earlier of (i) June 17, 2027 or (ii) the issuer’s next annual general meeting, subject to Spike Loy’s continued service.
  • Shares owned after transaction: not specified in the filing.
  • Filing parties and ownership: The Form 4 is filed jointly by multiple affiliated entities (Biotechnology Value Fund, BVF2, Trading Fund OS, BVF Partners L.P., BVF Inc., Mark N. Lampert, etc.) that make up a >10% Section 13(d) group (see footnotes F1–F4).
  • Related arrangement: Footnote F9 notes an agreement under which Spike Loy (a Managing Director of Partners and a MoonLake director) must transfer any economic benefit from these shares to Partners; Loy disclaims beneficial ownership except for any pecuniary interest.

Context
This is a derivative grant (an award of a right to acquire shares) rather than an open-market buy or sale. For retail investors, awards like this are typically compensation or retention tools for affiliates/board members and do not reflect an immediate cash purchase that signals a personal directional bet. Also note this transaction was reported by a 10% institutional owner and affiliated parties rather than a single executive; the filing was submitted late by several business days.